Mahana Therapeutics

By  Dave Muoio 03:50 pm February 12, 2021
Digital therapeutics have been plodding on a steady path toward acceptance within healthcare, but the modality reached new heights during a year of unprecedented adoption for digital health technologies. More and more software-based treatments are picking up regulatory approvals – including three De Novo clearances in 2020 alone – while the ongoing COVID-19 pandemic has exposed more consumers,...
A green traffic light
By  Dave Muoio 03:50 pm December 8, 2020
Editor's note: This story has been updated with quotes and additional information from Mahana's CEO and cofounder. The FDA has granted a De Novo clearance to San Francisco-based Mahana Therapeutics' Parallel, a prescription digital therapeutic for patients with irritable bowel syndrome (IBS) that delivers cognitive behavioral therapy (CBT). The agency made its decision on November 25, according...